NUBEQA EXTENDED OVERALL SURVIVAL BY LOWERING THE RISK OF DEATH
in mHSPC by 32%
when NUBEQA was added to hormone therapy* + docetaxel (chemotherapy) vs hormone therapy + chemotherapy alone
in nmCRPC by 31%
when NUBEQA was added to hormone therapy vs hormone therapy alone†
*Hormone therapy includes drug treatments or surgery to lower testosterone.
†The clinical study in nmCRPC was designed to measure metastasis-free survival (MFS) and also overall survival.
In the clinical study for mHSPC
NUBEQA extended overall survival (32% reduction in risk of death)
More men who added NUBEQA to hormone therapy + chemotherapy were still alive at
4 years vs hormone therapy + chemotherapy alone (63% vs 50%, respectively)
In the clinical study for nmCRPC
without cancer spreading to
other parts of their body (MFS) when they added NUBEQA to hormone therapy compared with men on hormone therapy alone
(median‡ 3.4 yrs vs 1.5 yrs)
‡Median is the middle value in a set of numbers, not the average.
Pronounced
(new-BECCA)
Press to hear pronunciation
NUBEQA Patient Brochure
Find out more about mHSPC, nmCRPC and Nubeqa
NUBEQA Side Effects
See possible side effects while taking NUBEQA.
Explore Financial Support
Plus more with Access Services by BayerTM.
PATIENT STORIES
You are not alone. See the stories of men taking NUBEQA and what their caregivers have to say.
Dr. Tom Green’s Story
Learn more about Dr. Green, a urologist and NUBEQA patient himself, as he talks about navigating diagnosis and treatment.
Dick and Jan’s Story
See how NUBEQA patient, Dick, navigates life after diagnosis as he continues to pursue his passions with the support of his loving wife, Jan.